TMSP(SH:600671) Xin Lang Zheng Quan·2025-10-27 02:06Group 1 - The core viewpoint of the news is that Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 115.15% and recent trading activity indicating a mixed sentiment among investors [1][2] - As of October 27, Tianmu Pharmaceutical's stock price was 18.89 CNY per share, with a market capitalization of 2.3 billion CNY and a trading volume of 22.31 million CNY [1] - The company has seen a net inflow of 342,900 CNY from major funds, with large orders accounting for 17.90% of total buying and 16.36% of total selling [1] Group 2 - Tianmu Pharmaceutical's main business segments include health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and other (0.12%) [1] - The company belongs to the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector, and is associated with concepts such as shell resources and small-cap stocks [2] - For the first half of 2025, Tianmu Pharmaceutical reported a revenue of 10.4 million CNY, representing a year-on-year growth of 73.97%, and a net profit attributable to shareholders of 10.25 million CNY, up 155.39% year-on-year [2] Group 3 - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.63 million CNY in dividends, with no dividends paid in the last three years [3]